| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-03-27 | Adaptimmune (UK) | $61.8 million | IPO | Cancer - Oncology | Capital increase | |
| 2017-03-27 | adaptimmune | $61.8 million | private placement | Cancer - Oncology | Private placement | |
| 2017-03-23 | Syntimmune (USA - MA) | $26 million | series A financing round | Apple Tree Partners (USA - NY) Baxalta Ventures (USA - MA) Partners Innovation Fund (USA) additional undisclosed investors | Autoimmune diseases | Series A financing round |
| 2017-03-22 | Vect-Horus (France) | € 2.5 million | fundraising | Provençale et Corse, BPMed (France) | CNS diseases - Neurological diseases - Neurodegenerative diseases - Cancer - Oncology | Fundraising |
| 2017-03-22 | Heat Biologics (USA - NC) | IPO | Cancer - Oncology | IPO | ||
| 2017-03-22 | Relief Therapeutics (Switzerland) | CHF 500’000 | capital increase | GEM Global Yield Fund | Rare diseases | Fundraising |
| 2017-03-20 | Aurinia Pharmaceuticals (Canada) | $173.1 million | private placement | Autoimmune diseases - Immunological diseases | Private placement | |
| 2017-03-20 | Advicenne (France) | €16 million | financing round | IRDI SORIDEC Gestion (France) Cemag Invest (France) MI Care (Luxembourg) InnoBio Bpifrance (France) IXO Private Equity (France) private individuals. | Kidney diseases - Renal diseases - Neurological diseases | Fundraising |
| 2017-03-20 | Pulmocide (UK) | $30.4 million | series B financing round | SR One (UK) Longwood Fund SV Life Sciences (USA - MA) F-Prime Capital (USA - MA) Johnson &Johnson Innovation - JJDC (USA-NJ) Touchstone Innovations (UK) | Infectious diseases - Respiratory diseases | Fundraising |
| 2017-03-20 | Advicenne (France) | €16 Million | financing round | IRDI SORIDEC Gestion (France) Cemag Invest (France) MI Care (Luxembourg) InnoBio (Bpifrance) (France) IXO Private Equity (France) private individuals. | Rare diseases | Financing round |
| 2017-03-18 | Audentes Therapeutics (USA - CA) | $75.4 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2017-03-17 | Emergent Biosolutions (USA - MD) | $100 million | grant | Biomedical Advanced Research and Development Authority (BARDA) (USA) | Infectious diseases | Grant |
| 2017-03-15 | Autifony Therapeutics (UK) | £1.7 million | subvention | Innovate UK (UK) the Dementia Discovery Fund (UK) | CNS diseases - Mental diseases | Subvention |
| 2017-03-08 | Kite Pharma (USA - CA) | $409.7 million | private placement | Private placement | ||
| 2017-03-01 | Faron Pharmaceuticals (Finland) | £5.0 million | private placement | Cancer - Oncology | Private placement | |
| 2017-02-28 | Paion (Germany) | € 4.99 million | capital increase | CNS diseases | Capital increase | |
| 2017-02-27 | Exonics Therapeutics (USA - TX) | $ 5 million | financing round | CureDuchenne Ventures (USA - CA) | Rare diseases - Genetic diseases - Neuromuscular diseases | Financing round |
| 2017-02-22 | Oncternal Therapeutics (USA - CA) | $18.4 million | series B financing round | Cancer - Oncology - Rare diseases | Series B financing round | |
| 2017-02-21 | Auris Medical (Switzerland) | $9.1 million | private placement | Otorhinolaryngology | Private placement | |
| 2017-02-20 | Centauri Therapeutics (UK) | £4.2 million (€ million) | financing round | Animatrix Capital (UK) private investors | Infectious diseases | Financing round |
